Dexela appoints Peter Denyer as Director and Non-Executive Chairman

Dexela Limited
(‘Dexela’ or ‘the Company’)
Appointment of Chairman

Dexela Limited is pleased to announce the appointment of Peter Denyer as Director and Non-Executive Chairman of Dexela Limited. Dexela’s Chief Executive, Ed Bullard, commented 'Reflecting the changing focus of the company, we are delighted to have someone with such extensive technical and commercial expertise and experience join us. This is an exciting time for the company and we all look forward to introducing world class products aimed at improving the accuracy and cost effectiveness of breast cancer screening'.

Peter founded and built the Vision Group, the Edinburgh-based creator of CMOS Imager chips used widely in digital cameras and has gone on to help a number of technology companies. He currently serves as Non-Executive Director for the ERA Foundation and is Non-Executive Chairman or Non-Executive Director of several technology companies.

Peter takes over as Chairman from Mike Brady who remains on the board of Dexela as a Non-Executive Director with specific expertise in image analysis applied to mammography and digital breast tomosynthesis.

For more information about Dexela Limited, please contact:

Dexela Limited
Edward Bullard, Chief Executive
Tel: +44 (0) 20 7148 3107


Buchanan Communications
Mary-Jane Johnson, Catherine Breen
Tel: +44 (0) 20 7466 5000
Notes for Editors

About Dexela Limited
Dexela is developing accurate and sensitive 3D breast imaging technology for the early detection of cancer, known as Tomosynthesis. Conventional mammography has a significant rate of both false negatives and false positives, particularly in younger women. Dexela is developing innovative technology for 3D breast imaging, which promises to significantly reduce both false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of call-backs. Dexela has developed powerful techniques to acquire, process and visualize data from 3D X-ray breast imaging. Dexela is playing a central role in this field through relationships with medical device manufacturers.

For more information about Dexela Ltd please visit www.dexelaimaging.com.

Incidence of Breast Cancer
Breast cancer is the most common cancer in the UK. Each year, there are over 44,000 new cases and over 12,000 deaths from this disease. The lifetime risk for a woman of developing breast cancer is one in nine (11%). Breast cancer survival rates are better the earlier the cancer is diagnosed. Around 9 out of 10 of women diagnosed with stage I breast cancer survives beyond five years. This drops to around 1 out of 10 diagnosed with stage IV.